Results 21 to 30 of about 27,025 (201)

Tuberculin conversion rate after BCG vaccination of apparently healthy infants in a resource-poor setting

International Journal of Medicine and Health Development, 2022
Background: Although Bacillus Calmette Guerin (BCG) vaccine remains one of the most important public health preventive measures against tuberculosis (TB), the presence of a BCG scar may not imply an immune response.
Eziamaka J Enemuo, Kenechukwu Kosisochukwu Iloh, Agozie C Ubesie, Henrietta U Okafor, Anthony Nnaemeka Ikefuna   +4 more
doaj   +1 more source

Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK

Health Technology Assessment, 2017
Background: Until recently, evidence that protection from the bacillus Calmette–Guérin (BCG) vaccination lasted beyond 10 years was limited. In the past few years, studies in Brazil and the USA (in Native Americans) have suggested that protection from ...
Punam Mangtani, Patrick Nguipdop-Djomo, Ruth H Keogh, Lucy Trinder, Peter G Smith, Paul EM Fine, Jonathan Sterne, Ibrahim Abubakar, Emilia Vynnycky, John Watson, David Elliman, Marc Lipman, Laura C Rodrigues   +12 more
doaj   +1 more source

COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination

Microorganisms, 2021
Bacille Calmette–Guérin (BCG) vaccination, widely used throughout the world to protect against infant tuberculous meningitis and miliary tuberculosis (TB), can provide broad non-specific protection against infectious respiratory diseases in certain ...
Kent J. Koster, Hilary L. Webb, Jeffrey D. Cirillo   +2 more
doaj   +1 more source

BCG vaccine in Korea

Clinical and Experimental Vaccine Research, 2013
The anti-tuberculosis Bacille de Calmette et Guérin (BCG) vaccine was developed between 1905 and 1921 at Pasteur Institutes of Lille in France, and was adopted by many countries. BCG strains comprise natural mutants of major virulence factors of Mycobacterium tuberculosis and that BCG sub-strains differ markedly in virulence levels.
Joung, Sun Myung, Ryoo, Sungweon
openaire   +2 more sources

BCG and Adverse Events in the Context of Leprosy

Frontiers in Immunology, 2018
BackgroundNotwithstanding its beneficial immunoprophylactic outcomes regarding leprosy and childhood TB, BCG vaccination may cause adverse events, particularly of the skin.
Renate Richardus, Renate Richardus, Anouk van Hooij, Susan J. F. van den Eeden, Louis Wilson, Korshed Alam, Jan Hendrik Richardus, Annemieke Geluk   +7 more
doaj   +1 more source

Epidemiology of childhood tuberculosis after ceasing universal Bacillus Calmette–Guérin vaccination

Scientific Reports, 2021
Universal Bacillus Calmette–Guérin (BCG) vaccination is recommended in countries with high tuberculosis (TB) burden. Nevertheless, several countries have ceased universal BCG vaccination over the past 40 years, with scarce comparative epidemiological ...
Sayori Kobayashi, Takashi Yoshiyama, Kazuhiro Uchimura, Yuko Hamaguchi, Seiya Kato   +4 more
doaj   +1 more source

Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination

Frontiers in Immunology, 2023
Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil.
Nicole L. Messina, Nicole L. Messina, Mariana G. Sperotto, Mariana G. Sperotto, Marco A. M. Puga, Marco A. M. Puga, Patricia V. da Silva, Patricia V. da Silva, Roberto D. de Oliveira, Roberto D. de Oliveira, Cecilia L. Moore, Laure F. Pittet, Laure F. Pittet, Laure F. Pittet, Tenaya Jamieson, Margareth Dalcolmo, Margareth Dalcolmo, Glauce dos Santos, Bruno Jardim, Marcus V. G. Lacerda, Nigel Curtis, Nigel Curtis, Nigel Curtis, Julio Croda, Julio Croda, Julio Croda   +25 more
doaj   +1 more source

BCG Vaccine – The Road Not Taken

Microorganisms, 2022
The Bacillus Calmette-Guérin (BCG) vaccine has been used for over one hundred years to protect against the most lethal infectious agent in human history, tuberculosis. Over four billion BCG doses have been given and, worldwide, most newborns receive BCG.
Coad Thomas Dow, Laith Kidess
openaire   +3 more sources

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion

Advanced Materials, EarlyView.
An engineered Trojan Mycobacterium, developed via a “peeling‐off and masking‐up” strategy, functions as a powerful splenic myelopoiesis converter. This spleen‐targeted nanomedicine induces trained immunity to reprogram immunosuppressive myeloid reservoirs into antitumoral effectors.
Jin‐Ho Choi, Sang Nam Lee, Jang Hun Heo, Soyoung Park, Sei Hyun Park, Yong Taik Lim   +5 more
wiley   +1 more source